SUBJECT INDEX

Abecarnil, anxiolytic properties 207
Abstract thinking, Alzheimer's disease 465
Acetylcholine, synthesis and release in hippocampus, nerve growth factor 853, 856
N-Acetylserotonin, pineal, clorgyline and age 897
Acoustic startle reflex, opiate–dopamine interactions 415–426
Addiction treatment, buprenorphine 531–538
Adenosine-3′,5′-monophosphate, neurotensin-sensitive protein phosphorylation 87
Adenylate cyclase
  5-HT_{1A} receptor interaction 741
  lithium and antidepressants 709–716
Adrafinil, motor activity 833
Adrenal gland
  function in abstinent alcoholic men 771–780
  phenelzine methyltransferase 308
α-Adrenergic receptors, motor activity 825–840
β-Adrenergic receptors
  leukocytes, amineptine 357–367
  pineal gland 898
Adrenocorticotropic hormone
  abstinent alcoholic men 771–780
  fast feedback regulation by cortisol 523–529
  fenfluramine and dexamethasone 639, 641
  D-fenfluramine response in depression 785
  ipsapirone response, anxiety and depression 725–731
Affective disorders
  cholinergic properties of drugs 545
  corticotropin releasing hormone 380
  genetic databases 173
  lithium administration by eye drops 315–321
  magnetic resonance imaging 584, 585
Age, monoamine metabolites in plasma 507
Aggression, phenylacetic acid in plasma 145
Aging
  dietary choline and behaviour 677–688
  glycosaminoglycan polysulfate in dementias 323–342
  melatonin synthesis 561–566
    MAO-A inhibitor 896–900
  memory 435
  nerve growth factor 161
Agnosia, Alzheimer's disease 459
AIDS
  peptide T pharmacokinetics 791–801
  SPECT scanning, dementia 650
Akathisia, neuroleptics 223
Alcohol, antagonism by ganglioside and sialic acid 91–104
Alcoholism, adrenal function during abstinence 771–780
Alcohol withdrawal, GABA 921–934
Alpidem, anxiolytic properties 207
Alzheimer's disease
  arecoline 643–648
  cytokines 490
  early detection battery for dementia 433–479
    clinical diagnosis 437
    cognitive assessment battery 445–466
  magnetic resonance imaging 586
  nerve growth factor 163, 858
Amineptine, leukocyte β-adrenoceptors 357–367
1-Aminocyclopropanecarboxylic acid, anxiolytic action 751
Amitriptyline
  5-HT_{1A} responsivity 731
  prophylactic efficacy 71–82
  supersensitivity to hypothermic effects of oxotremorine and nicotine 540, 544
Amphetamine
  acoustic startle reflex 419
  conditioning 841–850
  induced behaviours, effect of 5-HT depletion 105–117
Amphetamine–haloperidol, motor activity 910
β-Amyloid precursor protein, interleukin-6 490
Androgens, dopaminergic function 263
Animal models
  anxiety 205–212
  anxiolytics, infant separation 745–757
  attention deficit hyperactivity disorder 129
  behaviour, noradrenergic system 825–840
  depression 199–204
    role of 5-HT 735–744
  tardive dyskinesia, diltiazem 717–722
Anorexia
  corticotropin releasing hormone 379–391
  mood 15–23
  pituitary abnormalities 351–356
Anterior hypothalamic–preoptic area, muscarinic receptors and locomotion 279–284
Anticonvulsants, 2-propyl-1-aminopentane and 2-((2-propyl)pentylamino) acetamide 303–306
Antidepressants
  blockade of 5-HTP induced depression 738
  forskolin binding in brain 709–716
  5-HT induced PI response 393–403
  leukocyte β-adrenoceptors 357–367
  mechanisms of action 739
  metabolism in rat 285–289
  olfactory bulbectomy model 202
  orthostatic hypotension 64, 66, 68
  pineal melatonin synthesis 895–902
  prophylactic efficacy 71–82

psychotic depression 765–770
schizophrenia 2–6
schizophrenic substance abuse 7–9
simulated home treatment of depression 63–70
thyroid hormones 596
Anxiety
animal models 205–212, 745–757
ethanol and ganglioside 93, 95
ethanol withdrawal, GABA 922, 930
5-HT_{1A} receptors 723–733
magnetic resonance imaging 587
Anxiolytic drugs
animal models 205–212
infant rat separation test 745–757
Apomorphine
acoustic startle reflex 419
growth hormone response, effect of methyltestosterone 263–268
induced behaviours, effect of 5-HT depletion 105–117
low-dose, autoreceptor activation and behavioural consequences 689–698
Appetite suppression, corticotropin releasing hormone 387
Arcaine 187
Arecoline, Alzheimer's disease 643–648
Arousal, depression 257
Astrocytes, interleukin-6 production 483, 485
Atropine
antagonism of physostigmine effects 875
carbachol and locomotion 281
Attention
Alzheimer's disease 462
HIV-positive drug abusers 653, 655
Attention deficit hyperactivity disorder
animal model 129
methylphenidate metabolism 213–220
Auditory evoked potentials, lateralization 761
Autoimmunity, candidate loci 175, 177
Autonomic nerve dysfunction, stress 699–708
Autoradiography, cholecystokinin binding sites in brain 291–296
Autoreceptors, apomorphine 689–698

Behavioural modes, α-noradrenergic system 825–840
Behavioural Pattern Monitor 905, 906
Benzodiazepine agonists, GABA modulation of receptor affinity 924
Benzodiazepine receptor ligands, anxiolytic properties 207
Benzodiazepines
animal models of anxiety 748
sleep 817, 821
sodium divalproex interaction 269–273
thyroid hormones 596
Beta-blockers, heart rate 699–708
Bipolar affective disorder, lithium administration by eye drops 315–321
Blood group markers 177
Blood pressure, nortriptyline 67
Body temperature, ethanol and ganglioside 93, 94
Bretazenil, anxiolytic properties 207
Bromocriptine, effect on nucleus accumbens neurons 122
BRON, abuse of 513–521
Bulimia, pituitary abnormalities 351–356
Buprenorphine, treatment of heroin dependence 531–538
Buspirone, animal models of anxiety 209, 749

Caerulein, hypnogenic action 817
Caffeine, in BRON 513–521
Calcium, neurotensin-sensitive protein phosphorylation 85
Calcium channel inhibitors
haloperidol-induced dopaminergic supersensitivity 718, 719
schizophrenia 343
Candidate loci, neuropsychiatric diseases 172, 174, 176
Carbachol, muscarinic receptors and locomotion 279–284
Carbon dioxide, panicogenic effect 237–239
Carteolol, heart rate 702, 704
Cat
5-HT depletion and apomorphine or amphetamine induced behaviours 105–117
naloxone effects on visual evoked potentials 567–579
Catecholamines, MAOI 146
Caudate nucleus, neurotensin-sensitive protein phosphorylation 83–89
Cerebellum, *in vivo* modulation of cGMP 229–235
Cerebral blood flow, SPECT, HIV 649–662
Cerebrospinal fluid
cholecystokinin in 601–609
phenylacetic acid in, schizophrenia 41–47
CGS 12066B, animal model of anxiety 749
p-Chlorophenylalanine
effect on apomorphine and amphetamine induced behaviours 105–117
5-HT induced phosphoinositide hydrolysis 393–403
Chlorpheniramine, in BRON 513–521
Cholecystokinin
in CSF, psychosis and antipsychotic response 601–609
food intake in undernourished rats 405–413
panicogenic effect 237–239
Cholecystokinin receptors, localization in brain, autoradiography 291–296
Choline, dietary, behavioural effects during aging 677–688
Choline acetyltransferase, nerve growth factor 162, 163, 853, 856
Cholinergic function
Alzheimer's disease 643
nerve growth factor 851–860
thermoregulation 873–884
Cholinergic neurons, nerve growth factor and neostriatum 157–169
Cholinergic stimulation, locomotion 279–284

Circadian rhythm, adrenal function in alcoholism 776
Clonidine
information processing 497–502
motor activity 828–838
Clorgyline, pineal melatonin synthesis, aging 895–902
Cocaine–haloperidol, motor activity 910–912
Codeine, in BRON 513–521
Cognitive functioning
Alzheimer's disease 435
assessment battery 445–466
diagnostics 436
anorexia nervosa 20
arecoline 643–648
elderly, glycosaminoglycan polysulfate 323–342
Conditioning with amphetamine 841–850
Confrontational naming, Alzheimer's disease 450
Contingent negative variation, depression 257
Core temperature 541, 545
Cortical ablation, NMDA stimulated release of dopamine 666, 669
Corticosterone, physostigmine and thermoregulation 877, 881
Corticotropin releasing hormone
anorexigenic effects in monkey 379–391
induced β-endorphin release, interleukin-1 potentiation of 554, 557
response in abstinent alcoholic men 771–780
Cortisol
abstinent alcoholic men 771–780
fast feedback regulation of ACTH 523–529
fenfluramine and dexamethasone 640
D-fenfluramine response in depression 786
ipsapirone response, anxiety and depression 725–731
Cough suppressant, BRON, abuse of 513–521
Cytokines 482
Alzheimer's disease 490
potentiation of β-endorphin secretion 551–560
production by stimulated astrocytes 485

Debrisoquine, MAO inhibition 297–301
Dementia
arecoline 643–648
early detection battery 433–479
assessment, organic diagnosis 437
cognitive assessment battery 445–466
screens 440
HIV drug abusers, SPECT 649–662
magnetic resonance imaging 586
old age, glycosaminoglycan polysulfate treatment 323–342
Denial of illness, anorexia nervosa 15–21
Deprenyl, phenylethylamine in brain 146, 152
Depression
animal models 199–204
role of 5-HT 735–744
anorexia nervosa 19
cholinergic properties of drugs 545
corticotropin releasing hormone 380
D-fenfluramine and HPA axis hormones 781–790
genetic databases 173
5-HT 394, 401, 735–744
HPA axis 637–642
5-HT_{1A} receptors 726
5-HT_2 receptors 49–61
leukocyte β-adrenoceptors and amineptine treatment 357–367
lithium side effects 428
magnetic resonance imaging 584, 585, 588
α-methyltryptophan as a therapeutic agent 936
phenylethylamine and phenylacetic acid 144
post-psychotic, TRH test 369–378
preparatory brain potentials 257–262
prophylactic efficacy of tricyclic antidepressants 71–82
pseudodementia 439, 463
psychotic, tricyclic antidepressants 765–770
seasonal platelet 5-HT uptake 25–39
simulated home treatment with nortriptyline 63–70
substance-abusing schizophrenic patients 1–13
temporal segmentation of response speed 249–255
p-tyramine challenge test 241–247
Desipramine
forskolin binding in brain 709–716
prophylactic efficacy 71–82
Development
cholecystokinin satiety in undernourished rats 405–413
nerve growth factor 161
somatic and behavioural, dopamine D1 receptors 129–138
Dexamethasone suppression test
post D-fenfluramine hormone levels 786
role of 5-HT in HPA axis escape 637–642
Diabetes mellitus, autoimmunity 177, 178
Diazepam
heart rate 702, 705
thyroid hormone changes in panic disorder 598
Diet, phenylalanine, plasma metabolites 611–623
Dihydroergotamine, migraine 192
Diltiazem, oral stereotypies 717–722
Dissociative anaesthetics, NMDA receptor 184
Dog, cholecystokinin receptors in brain 291–296
Domperidone, effect on nucleus accumbens neurons 124
Dopamine
apomorphine induced hypomotility 690–698
inhibition of nucleus accumbens neurons 122
MAOI 146
opiate interactions in acoustic startle reflex 415–426
phenylethylamine effect on transmission 149, 152
release from nucleus accumbens, NMDA receptors 663–673
turnover in brain, effects of SCH 23390 and ritanserin 861–872
Dopamine agonists, motor behaviour 903–919

Dopamine antagonists
dopamine and 5-HT turnover 861–872
methamphetamine interaction 803–815
Dopamine D1 receptor
mediated inhibition of nucleus accumbens neurons from ventral tegmental area 119–128
somatic and behavioural ontogeny 129–138
Dopamine D2 receptor mRNA, distribution in primate brain 885–893
Dopaminergic function, androgens 263
Dopaminergic transmission, Ca^{2+} channel inhibitors 718, 720
Doxepin, prophylactic efficacy 71–82
Drug abuse, HIV, SPECT 649–662
Dynamical entropy, dopamine and motor behaviour 915
Dysnomia, Alzheimer's disease 451
Dystonia, neuroleptics 222

Eating disorders, pituitary abnormalities 351–356
Elderly, glycosaminoglycan polysulfate in dementias 323–342
β-Endorphin
interleukin-1 potentiation of secretion 551–560
response to D-fenfluramine in depression 785
Environmental temperature, antagonism of physostigmine effects 873–884
Ergot compounds, migraine 192
Ethanol, antagonism by ganglioside or sialic acid 91–104
Ethanol withdrawal, GABA 921–934
Event related potentials
clonidine and scopolamine 499
depression 251, 253
Excitatory amino acids
animal model of anxiety 750
in vivo modulation of cGMP 229–235
NMDA receptor 186
Excitatory amino acid agonists, dopamine release from nucleus accumbens 663–676
Exploration, ethanol and ganglioside 93, 95
Extinction learning, dietary choline 681, 683, 685

Fast feedback, ACTH/cortisol 523–529
Feeding behaviour
cholecystokinin 405–413
corticotropin releasing hormone 385, 386
Fenfluramine
effect on HPA axis 639
HPA axis hormones and prolactin responses in depressed patients 781–790
Flunitrazepam
binding to GABA receptors during ethanol withdrawal 924
hypnotic action reversed by proglumide 817–823
Fluoxetine, 5-HT_{1A} responsivity 731
Fluphenazine, schizophrenia 224
Forskolin, binding in brain, effect of lithium and antidepressants 709–716

GABA, ethanol withdrawal 921–934
Ganglioside, attenuation of intoxicating effects of ethanol 91–104
Genetic databases, inborn errors of metabolism 171–181
Glial cells, interleukin-6 production 483, 485
Glucocorticoids, thermoregulation 881
Glutamate
NMDA receptor 184
stimulated dopamine release 667
Glycine
cerebellar cGMP 230
NMDA receptor 184
Glycosaminoglycan polysulfate, treatment of old age dementias 323–342
G proteins
5-HT_{1A} receptors 728
lithium and antidepressants 713
lithium and light sensitivity in affective disorder 317
Growth hormone, response to apomorphine, effect of methyltestosterone 263–268
Guanosine-3′,5′-monophosphate, cerebellum, *in vivo* modulation 229–235

Hallucinations, BRON 518
Haloperidol
CSF cholecystokinin and antipsychotic response 605
diltiazem and oral stereotypies 717–722
effect on nucleus accumbens neurons 122–126
plasma levels in schizophrenics 225
Haloperidol–amphetamine, motor activity 910
Haloperidol–cocaine, motor activity 910, 912
Haloperidol reductase, red blood cells 275–278
Headache, 5-HT receptors 191–197
Heart rate, beta-blockers and diazepam 699–708
Height, monoamine metabolites in plasma 508
Heroin, prepulse inhibition 420, 422
Heroin addiction, buprenorphine 531–538
Hippocampus
antidepressants and 5-HT-induced PI response 393–403
nerve growth factor and cholinergic function 851–860
HIV
peptide T 791–801
SPECT scanning, dementia 649–662
Home treatment, depression 63–70
Homovanillic acid
in brain, effect of SCH 23390 and ritanserin 864
in plasma, age, sex, weight and height correlates 503–512
Hospitalization/home treatment, depression 63
Human gene mapping library 173
Huntington's chorea, nerve growth factor 163
Hydralazine, methylation 309
Hydrocortisone hemisuccinate, ACTH regulation 523–529
8-Hydroxy-(di-*N*-propylamino)tetralin, inhibition by adenylate cyclase 741

5-Hydroxyindoleacetic acid
interhemispheric asymmetry in brain 761
pineal, clorgyline and age 897
plasma, age, sex, weight and height correlates 503–512
p-Hydroxyphenelzine, MAO inhibition 297–301
m-Hydroxyphenylacetic acid, plasma, age, sex, weight and height correlates 503–512
5-Hydroxytryptamine
animal model of anxiety 209, 748, 750
depletion and apomorphine or amphetamine induced behaviours 105–117
depression
animal model 735–744
interhemispheric asymmetry in human brain 759–764
α-methyltryptophan as a therapeutic agent 935
phosphoinositide hydrolysis in platelets, depression 49–61
phosphoinositide response in hippocampus, effect of antidepressants 393–403
pineal, clorgyline and age 897
role in HPA axis escape from dexamethasone suppression 637–642
seasonal platelet uptake in depression 25–39
turnover in brain, effect of SCH 23390 and ritanserin 861–872
5-Hydroxytryptamine 1A receptors
antidepressants 740
anxiety, animal model 748, 750
anxiety disorders and depression 723–733
candidate loci, schizophrenia 176
5-Hydroxytryptamine 1A receptor agonists, anxiolytic potential 209
5-Hydroxytryptamine 1B receptors, animal model of anxiety 749, 750
5-Hydroxytryptamine 1C receptor antagonists, migraine 194
5-Hydroxytryptamine 1D receptors, migraine 191
5-Hydroxytryptamine 2 receptors
dopamine turnover 861–872
platelets, depresssion 49–61
5-Hydroxytryptamine 2 receptor antagonists, migraine 193
5-Hydroxytryptamine 3 receptor antagonists, migraine 194
5-Hydroxytryptophan
animal model of depression 738
melatonin synthesis and aging 561–566
Hyperthermia, amphetamine induced 841–850
Hypothalamic phospholipid liposomes, reduction of lithium side effects 428
Hypothalamus
eating disorders 351
ontogeny of cholecystokinin induced modulation of food intake 406, 410
Hypothalamus–pituitary–adrenal axis
alcoholism 771, 776
response to D-fenfluramine in depressed patients 781–790
role of 5-HT in escape from dexamethasone suppression 637–642
Hypomotility, apomorphine induced 692, 694
Hypothermia
ipsapirone induced, anxiety and depression 725–731
physostigmine induced 875

Idazoxam, motor activity 828
Ifenprodil 186, 232, 233
Imipramine
effect on 5-HT induced PI response 379, 401
interhemispheric asymmetry in binding in human brain 760
post-psychotic depression, TRH test 373, 374
prophylactic efficacy 71–82
schizophrenia 3, 4
substance abuse 8
seasonal platelet binding in depression 25–39
thyroid hormone changes in panic disorder 598
Immunogenetic disease 177
Inborn errors of metabolism, genetic databases 171–181
Indoleacetic acid, plasma, age, sex, weight and height correlates 503–512
Infantile autism, magnetic resonance imaging 586
Infant separation, test for anxiolytics 745–757
Information processing
clonidine and scopolamine 497–502
depression 249
Inositol monophosphate, 5-HT induced accumulation in platelets in depression 49–61
Integrated genetic databases 171–181
Interleukin-1
Alzheimer's disease 490
internalization in pituitary cells 553, 557
potentiation of β-endorphin secretion 551–560
Interleukin-6 482
Alzheimer's disease 490
neurite outgrowth and neuronal viability 486
production by stimulated astrocytes 483, 485
Iprindole, effect on 5-HT induced PI response 397, 401
Ipsapirone, response in anxiety disorders and depression 725, 726

Kainate receptors, modulation of cerebellar cGMP 230

Language skills, Alzheimer's disease 446
Lateralization
anorexia nervosa 15–21
5-HT in human brain 759–764
Learning, dietary choline in aging rats 677–688
Leukocytes, depression, β-adrenoceptors and amineptine treatment 357–367
Light
melatonin synthesis, effect of aging 561–566
sensitivity in bipolar affective disorder, lithium administration by eye drops 315–321
Limbic dysfunction, model of depression 200, 202

Lithium
administration by eye drops 315–321
forskolin binding in brain 709–716
induced malignant syndrome 428–430
prophylactic efficacy 79
Locomotion
amphetamine and apomorphine induced changes, effect of 5-HT depletion 105–117
animal model of attention deficit hyperactivity disorder 129
ethanol-induced decrement, effect of ganglioside and sialic acid 91–104
low-dose apomorphine 691
muscarinic receptors in basal forebrain 279–284

Magnetic resonance imaging 581–593
affective disorder 584, 585
dementia 586
infantile autism 586
neurotic disorders 587
pituitary abnormalities in eating disorders 351–356
schizophrenia 584, 585
Malignant hyperthermia, psychotropic drugs 427
Mandelic acid, in plasma, age, sex, weight and height correlates 503–512
Mania, magnetic resonance imaging 588
MDL 72222, migraine 194
Mecamylamine, augmentation of hypothermic response to oxotremorine 542
Melatonin
clorgyline-induced synthesis, aging 895–902
5-HTP, light and aging 561–566
Memory
aging 435
Alzheimer's disease 453
arecoline 643–648
clonidine and scopolamine 497
HIV positive drug abusers 655
Methadone, HIV positive abusers, SPECT 649–662
Methamphetamine, antagonism by SCH 23390 and raclopride 803–815
N-Methyl-D-aspartate receptor
animal model of anxiety 750
glutamate, glycine and polyamines 183–190
modulation of cerebellar cGMP 230
regulation of dopamine release from nucleus accumbens 663–676
Methylation, phenelzine 307–312
Methylatropine, antagonism of physostigmine effects 875
Methylephedrine, in BRON 513–521
DL-*threo*-Methylphenidate, metabolism in humans 213–220
Methyltestosterone, growth hormone response to apomorphine 263–268
α-Methyltryptophan, therapeutic agent 935–938
Metoclopromide, migraine 194
Migraine, 5-HT receptors 191–197
MK-801
dopamine release from nucleus accumbens 668
NMDA receptor binding 184
Monkey
behavioural effects of CRH 379–391
dopamine D2 receptor mRNA in brain 885–893
Monoamine oxidase
deamination of 2-propyl-1-aminopentane and 2-((2-propyl)pentylamino) acetamide 303–306
methylated phenelzine 309
paranoid schizophrenics 45
Monoamine oxidase inhibitors
effect on dopamine and phenylethylamine in brain 146
peripheral 297–301
pineal melatonin synthesis, aging 895–902
Monoamines, acidic metabolites in plasma 503–512
Mood, anorexia nervosa 15–23
Motor activity
dopaminergic agents, scaling approach 903–919
α-noradrenergic system 825–840
Motor skills, Alzheimer's disease 461
Multi-infarct dementia, glycosaminoglycan polysulfate 323–342
Muscarinic–nicotinic mechanisms 539–549
Muscarinic receptors, basal forebrain, locomotion 279–284

Naloxone
inhibition of amphetamine-induced loss of prepulse inhibition 420
visual evoked potentials 567–579
Narcolepsy 177
Neostriatum, nerve growth factor 157–169
Nerve growth factor 851
Alzheimer's disease 858
cholinergic function in hippocampus 853
clinical implications 163
distribution and binding sites in neostriatum 158
injury 161
neuronal transport 160
ontogenetic changes 161
Nerve growth factor receptors 159
Neuroleptic Malignant Syndrome 427
Neuroleptics
schizophrenia 221–228
blood levels 225
dosage strategies 223
side effects 222
verapamil interaction 343–349
supersensitivity, diltiazem 717–722
Neurons, interleukin-6 486
Neuropsychological testing, HIV-positive drug abusers 649–662
Neurotensin, sensitive protein phosphorylation 83–89
Nicotine, hypothermic effect, amitriptyline-induced supersensitivity 540, 545
Nitric oxide, modulation of cGMP by excitatory amino acids 231
Noradrenaline, motor activity 826

Nortriptyline
prophylactic efficacy 71–82
simulated home treatment of depression 63–70
Nucleus accumbens
dopamine D1 receptor mediated inhibition of neurons from ventral tegmental area 119–128
dopamine release and NMDA receptors 663–673

Obsessive-compulsive disorder, 5-HT_{1A} receptors 730
Olfactory bulbectomy, model of depression 202
Online Mendelian Inheritance in Man 173
Ontogeny, cholecystokinin satiety in undernourished rats 405–413
Open field, dietary choline and behaviour 679, 683, 684
Opiate, dopamine interactions in acoustic startle reflex 415–426
Opiate dependence, buprenorphine 531–538
Opioid peptides, visual processing 567–579
Optic chiasm, naloxone and visual evoked potentials 570
Oral stereotypies, quinpirole-induced, effect of diltiazem 717–722
Orthostatic hypotension, nortriptyline 64, 66, 68
Over-the-counter cough suppressant, abuse of 513–521
Oxotremorine, hypothermic effect, mecamylamine sensitivity 541, 542

P300 761
Panic disorder
cholecystokinin and carbon dioxide 237–239
5-HT_{1A} receptors 728
sodium divalproex–benzodiazepine interaction 269–273
thyroid hormones during treatment 595–600
Paranoid schizophrenia
phenylacetic acid in CSF and serum 41–47
phenylacetic acid and phenylethylamine in brain 143
Parkinson's disease, phenylethylamine and catecholaminergic neurotransmission 152
Pentobarbital, hypothermic effect, amphetamine conditioning 846
Peptide T, AIDS 791–801
Perceptual function, Alzheimer's disease 459
Pharmaco-EEG, serotonergic interhemispheric asymmetry 759–764
Phencyclidine, NMDA receptor in schizophrenia 184
Phenelzine
MAO inhibition 297–301
methylation 307–312
Phenolsulfotransferase, platelets, depression 241–247
Phenylacetic acid
in CSF and serum in schizophrenia 41–47
marker in neuropsychiatric disorders 143
in plasma
age, sex, weight and height correlates 503–512
effect of dietary phenylalanine 611–623
Phenylalanine
cholecystokinin satiety ontogeny in rats 405–413
dietary, plasma phenylalanine, phenylethylamine and phenylacetic acid 611–623
Phenylethanolamine *N*-methyltransferase, phenelzine methylation 307–312
Phenylethylamine
analysis 140
dietary phenylalanine 611–623
distribution and metabolism 142
electrophysiological effects 149
marker in neuropsychiatric disorders 143
MAOI effects 146
modulation of catecholaminergic neurotransmission 139–156
neuromodulator in dopaminergic neurotransmission 45
urinary, paranoid schizophrenia 44
Phosphoinositide
5-HT stimulated hydrolysis in hippocampus, effect of antidepressants 393–403
5-HT stimulated hydrolysis in platelets in depression 49–61
Photosensitivity, bipolar affective disorder 315
Physostigmine, hypothermic and neuroendocrine responses, antagonism 873–884
Pindolol, heart rate 702, 704
Pineal gland, melatonin response to clorgyline, aging 895–902
Pirenzepine, carbachol and locomotion 283
Pituitary cells, interleukin-1 potentiation of endorphin secretion 551–560
Pituitary gland, eating disorders 351–356
Platelets
5-HT_2 function in depression 49–61
seasonal 5-HT uptake and imipramine binding in depression 25–39
Polyamines
cerebellar cGMP 233
modulation of NMDA receptor 184
Postmortem brain, serotonergic interhemispherical asymmetry 759–764
Post-psychotic depression, thyroid releasing hormone test 369–378
Potassium, dopamine release from nucleus accumbens 667, 672
Practice, psychometric testing 625–635
Praxis, Alzheimer's disease 461
Prazosin, motor activity 835
Prepulse inhibition, acoustic startle 415, 419
Primary degenerative dementia
early detection battery 433–479
glycosaminoglycan polysulfate 323–342
Problem solving, Alzheimer's disease 465
Procyclidine, antagonism of physostigmine effects 875
Prodrug, valproic acid 304
Proglumide, reversal of hypnotic action of flunitrazepam 817–823

Prolactin, response to D-fenfluramine in depression 786
Prophylactic efficacy, tricyclic antidepressants 71–82
Propranolol, heart rate 702, 705
2-Propyl-1-aminopentane, deamination and anticonvulsant activity 303–306
2-((Propyl)pentylamino)acetamide, deamination and anticonvulsant activity 303–306
Protein, neurotensin-sensitive phosphorylation 83–89
Protein kinase C, depletion and interleukin-1 potentiation of β-endorphin secretion 554, 557
Psychometric testing, practice effect 625–635
Psychomotor retardation, depression 249, 257
Psychotic depression, tricyclic antidepressants 765–770
Punishment, anxiolytic drugs 207

Quinpirole
induced oral stereotypies, effect of diltiazem 717–722
motor activity 909, 914
Quisqualate receptors, modulation of cerebellar cGMP 230

Raclopride, methamphetamine antagonism 803–815
Rat strains, somatic and behavioural ontogeny and dopamine D1 receptors 129–138
Reaction time
clonidine and scopolamine 499
depression 249, 257
Red blood cells, haloperidol reductase 275–278
Ritanserin, effect on dopamine and 5-HT turnover in brain 861–872
RO 15-1788, animal model of anxiety 748
Ro 15-4513, binding to GABA receptors during ethanol withdrawal 924

SCH 23390
effect on dopamine and 5-HT turnover in brain 861–872
methamphetamine antagonism 803–815
effect on nucleus accumbens neurons 122–126
ontogeny of dopamine D1 receptor 134
Schizophrenia
antidepressants and substance abuse 1–13
candidate serotonergic gene 176
cholecystokinin in CSF 601–609
genetic databases 173
haloperidol reductase in red blood cells 275–278
magnetic resonance imaging 584, 585
neuroleptics 221–228
NMDA receptor 184
phenylacetic acid in CSF and serum 41–47
phenylacetic acid and phenylethylamine in brain 143, 152
thyroid releasing hormone test in post-psychotic depression 369–378
verapamil 343–349
Scopolamine
antagonism of physostigmine effects 875
information processing 497–502
Seasonal variation, platelet 5-HT uptake in depression 25–39
Semicarbazide-sensitive amine oxidase 303–306
Senile dementia, early detection battery 433–479
Sensitization, amphetamine 842, 847
Sensorimotor gating, opiate–dopamine interaction 416, 422
Sensory modulation, naloxone 568, 573
Separation
animal model of depression 201
test for anxiolytics 745–757
Serotonergic agents, migraine 191–197
Sex differences
CSF cholecystokinin in schizophrenics 604
monoamine metabolites in plasma 506
serotonergic lateralization 761
Sialic acid, attenuation of intoxicating effects of ethanol 91–104
SKF 38393
motor activity 909, 914
nucleus accumbens neurons 122–126
Sleep
ethanol and ganglioside 95
flunitrazepam and proglumide 817–823
Slow release, methylphenidate 220
Sodium divalproex, benzodiazepine interaction 269–273
Spatial scaling component, dopamine and motor behaviour 914
Species differences
antidepressant metabolism 285
cholecystokinin receptors in brain 291
corticotropin releasing hormone 386
SPECT scanning, HIV-positive drug abusers 649–662
Spermidine, NMDA receptor 185
Stereotypy, apomorphine 693
Stress
animal models of depression 201
beta-blockers, diazepam and heart rate 699–708
induced hyperthermia 848
Stroke, NMDA receptor 184
Substance abuse
BRON 513–521
HIV, SPECT 649–662
schizophrenics, antidepressants 6–9
Sumatriptan, migraine 192
Suriclone, anxiolytic properties 207

Tardive dyskinesia
diltiazem 717–722
neuroleptics 223
verapamil 343–349
Temporal discrimination, dietary choline 679, 681, 684
Tetrabenazine, animal model of depression 736

Thermoregulation
muscarinic–nicotinic mechanisms 539–549
physostigmine 873–884
Thyrotropin releasing hormone test, post-psychotic depression 369–378
Thyroxine, changes during treatment of panic disorder 595–600
Tourette syndrome, genetic databases 173
Transducin, lithium interaction with G proteins 317, 318
Tranylcypromine, forskolin binding in brain 709–716
Trazodone, schizophrenia 3
Tricyclic antidepressants
induced malignant syndrome 427
metabolism in rat 285–289
orthostatic hypotension 64, 66, 68
prophylactic efficacy 71–82
psychotic depression 765–770
schizophrenia 3
simulated home treatment of depression 63–70
Trimipramine, metabolism in rat 285–289
Tryptophan hydroxylase, inhibition and evoked behaviours 105–117
p-Tyramine challenge test, depression 241–247

Ultrasonic vocalization, test for anxiolytics 745–757
Undernutrition, cholecystokinin and food intake 405–413

Valproic acid
formation from 2-((2-propyl)pentylamino)acetamide and 2-propyl-1-aminopentane 304
Vanillylmandelic acid, in plasma, age, sex, weight and height correlates 503–512
Vasopressin, induced β-endorphin release, interleukin-1 potentiation of 554, 557
Ventral tegmental area, dopamine D1 receptor mediated inhibition of nucleus accumbens neurons 119–128
Verapamil, schizophrenia 343–349
Verbal memory
Alzheimer's disease 453
arecoline 643–648
HIV-positive drug abusers 653, 655
Visual evoked potentials, naloxone 567–579
Visuospatial deficits, Alzheimer's disease 457
Visuospatial function, arecoline 643–648
Vocabulary, dementia 446

Weight, monoamine metabolites in plasma 508
Withdrawal, ethanol, GABA 921–934
Word fluency, Alzheimer's disease 448

Yawning, apomorphine-induced 692